Alnylam Interview: RNAi Leader Expands Into NASH, CNS And Eye Diseases

Buoyed By $1bn Regeneron Alliance

 
• By Andrew McConaghie
  
Alnylam
Alnylam's Boston, MA headquarters. It will take another 5-10 years for Alnylam to enter biopharma's 'big league' - but it has already put RNAi on the map • Source: Photo Courtesy of BioMed Realty, L.P. All Rights Reserved

More from Alimentary/Metabolic

More from Therapy Areas